190 related articles for article (PubMed ID: 20668631)
1. Anti-hypertensive drugs have different effects on ventricular hypertrophy regression.
Ferreira Filho C; Abreu LC; Valenti VE; Ferreira M; Meneghini A; Silveira JA; Riera AR; Colombari E; Murad N; Santos-Silva PR; Silva LJ; Vanderlei LC; Carvalho TD; Ferreira C
Clinics (Sao Paulo); 2010 Jul; 65(7):723-8. PubMed ID: 20668631
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
4. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.
Donohue TJ; Dworkin LD; Ma J; Lango MN; Catanese VM
J Investig Med; 1997 Dec; 45(9):584-91. PubMed ID: 9444886
[TBL] [Abstract][Full Text] [Related]
6. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats.
Kim S; Ohta K; Hamaguchi A; Yukimura T; Miura K; Iwao H
Br J Pharmacol; 1996 Jun; 118(3):549-56. PubMed ID: 8762077
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.
De Rosa ML; Cardace P; Rossi M; Baiano A; de Cristofaro A
J Hum Hypertens; 2002 Feb; 16(2):133-40. PubMed ID: 11850771
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T
Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945
[TBL] [Abstract][Full Text] [Related]
9. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
10. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
Avanza AC; El Aouar LM; Mill JG
Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
[TBL] [Abstract][Full Text] [Related]
12. Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis.
Sabino B; Lessa MA; Nascimento AR; Rodrigues CA; Henriques Md; Garzoni LR; Levy BI; Tibiriçá E
J Cardiovasc Pharmacol; 2008 Apr; 51(4):402-9. PubMed ID: 18427284
[TBL] [Abstract][Full Text] [Related]
13. Management of hypertension in patients with left ventricular hypertrophy.
Cuspidi C; Sala C; Zanchetti A
Curr Hypertens Rep; 2007 Dec; 9(6):498-505. PubMed ID: 18367014
[TBL] [Abstract][Full Text] [Related]
14. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B
Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
[TBL] [Abstract][Full Text] [Related]
16. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
[TBL] [Abstract][Full Text] [Related]
17. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
18. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
19. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
20. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
